drugset / Trial / NCT02110355
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
RandomizedParallel-groupOpen-labelTreatment
Summary
Phase 1b/2a, open-label, sequential dose escalation and expansion study of AMG 232 in combination with trametinib and dabrafenib in subjects with metastatic melanoma followed by a direct comparison of AMG 232 combined with trametinib and dabrafenib versus trametinib combined with dabrafenib alone.
Timeline
- Start
- 2014-12-19
- Primary completion
- 2018-12-27
- Completion
- 2018-12-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabrafenib | Small molecule | — | — |
| Subject | Navtemadlin | Small molecule | — | Oral |
| Background | Trametinib | Small molecule | — | — |